Furthermore, while hypoglycemia is rare, the main problem with insulin in type 2diabetes is weight gain. When tablets-relying therapy is no more efficient, the best insulin therapeutic protocol, in term of metabolic performance, limited weight gain, and patient agreement, consists in a Bed-time...
Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 37, 751–759 (2014). Article PubMed PubMed Central CAS Google Scholar Reger, M. A. et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE ...
SKYLER J.S. ET AL: ' Insulin therapy in type II diabetes. ' POSTGRADUATE MEDICINE., [Online] vol. 101, no. 2, February 1997, pages 1 - 17, XP002080749 Retrieved from the Internet:Skyler JS. Insulin therapy in type II diabetes: who needs it, how much of it and for how long?
Research suggests that insulin should be used sooner, rather than later, in the treatment of type 2 diabetes mellitus.
There are two completely different diseases known as diabetes. Type 1 is an autoimmune condition that often starts in childhood or adolescence. Type 2 is a metabolic disorder sometimes associated with lifestyle. In both cases, the insulin-secreting beta cells in the pancreas die, albeit at differ...
(fasting C-peptide >0.5 nmol/L) and who were using long-acting insulin. Exclusion criteria weretype 1 diabetes, a history ofketoacidosis, and use of noninsulin injectable glucose-lowering medication. The complete list of eligibility criteria can be found inAppendix 1(available online atwww.gie...
Insulin therapy in type 2 diabetesJill Hill
Insulin resistance and impaired insulin secretion are the main pathophysiological defects responsible for the development of hyperglycemia in type 2 diabetes.[1,2]With the continuous presence of insulin resistance, progressive loss of β-cell function is the crucial defect. The continuous decline in β...
Clinical trials have shown that insulin analogues, such as glargine, detemir, aspart, and lispro, do not offer major advantages over human insulin products, such as neutral protamine Hagedorn (NPH) and regular human insulin, for patients with type 2 diabetes.1,2 In these studies, nei...
development of insulin antibodies and changes in pulmonary function with long-term use. If inhaled insulin is approved by the FDA, it will represent another therapeutic option for patients with type 2 diabetes, but primary care physicians will need guidance in selecting appropriate candidates for the...